Background-Carotid-femoral pulse wave velocity (CFPWV) is a heritable measure of aortic stiffness that is strongly associated with increased risk for major cardiovascular disease events. Methods and Results-We conducted a meta-analysis of genome-wide association data in 9 community-based European ancestry cohorts consisting of 20 634 participants. Results were replicated in 2 additional European ancestry cohorts involving 5306 participants. Based on a preliminary analysis of 6 cohorts, we identified a locus on chromosome 14 in the 3Ј-BCL11B gene desert that is associated with CFPWV (rs7152623, minor allele frequencyϭ0.42, ␤ϭϪ0.075Ϯ0.012 SD/allele, Pϭ2.8ϫ10
S everal recent studies have demonstrated that carotidfemoral pulse wave velocity (CFPWV), an important indicator of stiffness of the wall of the thoracic and abdominal aorta, is associated with increased risk for major cardiovascular disease (CVD) events. [1] [2] [3] [4] Various risk factors for abnormal CFPWV have been identified, including standard CVD risk factors such as age, glucose intolerance, lipid disorders, and hypertension. 5 In addition, CFPWV is a moderately heritable trait with an estimated residual heritability (h 2 ) of approximately 0. 40, 6 although molecular mechanisms contributing to aortic stiffness remain largely undefined. To evaluate associations of common genetic variants with CFPWV, we performed a meta-analysis of genome-wide association study (GWAS) data from 9 community based cohorts, with replication genotyping in 2 additional cohorts. In addition, in light of the association between CFPWV and CVD risk, we interrogated existing clinical end point GWAS data to determine whether variants associated with CFPWV are associated with CVD risk.
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Methods
Consortium Organization
The AortaGen Consortium includes 9 cohort studies that completed genome-wide genotyping and had measured CFPWV, plus 2 cohort studies that had measured CFPWV and collected DNA for replication genotyping. Each study adopted collaboration guidelines and the consortium established a consensus on phenotype harmonization, covariate selection, and an analytic plan for within-study genomewide association and prospective meta-analysis of results across studies. Each study received institutional review board approval of its consent procedures, examination and surveillance components, data security measures, and DNA collection and its use for genetic research. All participants in each study gave written informed consent for participation in the study and the conduct of genetic research. Details of study cohort, CFPWV measurement protocols and inclusion and exclusion criteria are provided in the online-only Data Supplement Methods and Table 1 .
Phenotyping
Only cohorts that measured CFPWV based on the carotid-to-femoral transit time and distance were included in the meta-analysis. CFPWV increases nonlinearly and exhibits marked variance inflation with advancing age, resulting in a strongly right skewed distribution. In addition, differences in the method used to ascertain transit distance can alter values by up to 30% and the amount of error may be influenced by sex and other anthropomorphic factors such as height and weight. Thus, genetic association analyses were performed using a sex-specific standardized residual that was based on the inverse of CFPWV, which normalizes the distribution, and that was further adjusted for age, age squared, height, and weight. As a result of these transformations, the cohorts had a highly comparable distribution of the phenotype (mean of 0 and standard deviation of 1 with a normal distribution).
Genotyping and Imputation
Genotyping and imputation methods have been described previously and are summarized in online-only Data Supplement Table S1 . For genome-wide SNP sets, genotyping was carried out using commercially available arrays. Before imputation, quality control measures were applied as outlined in online-only Data Supplement Table S1 . MACH was used by all cohorts for imputation of genotypes to the HapMap set of approximately 2.5 million SNPs. For replication cohorts, genotyping was carried out on the platforms noted in online-only Data Supplement Table S1 . All genetic coordinates in tables and Figure refer to HapMap release 22 build 36.
Expression Methods
Details of expression studies, including RNA extraction, cDNA preparation, PCR amplification, and sequencing are provided in the online-only Data Supplement Methods.
Statistical Analyses
The phenotype for meta-analysis was a sex-specific (in Framingham, cohort-specific, and sex-specific) standardized regression residual for 1000/CFPWV, adjusted for age, age squared, height, and weight. Genome-wide association analyses were conducted within each cohort using an additive gene-dose model. Linear mixed effects models were fitted to account for relatedness in pedigrees. Withinstudy associations were combined by prospective meta-analysis using inverse-variance weighting. Meta-analyses were performed using the software program MetABEL (http://www.genabel.org/ packages/MetABEL). During meta-analysis, SNPs were excluded if weighted mean minor allele frequency was Ͻ1%, resulting in 2.41 million SNPs for analysis. The genomic control parameter was calculated to adjust each study and after meta-analysis, was recalculated to adjust for among-study heterogeneity. For the initial meta-analysis, a predetermined threshold of 4.0ϫ10 Ϫ7 (stage 1) was used to select SNPs for attempted replication. 7 Based on a preliminary analysis of 6 cohorts, we selected SNPs from 2 loci (the SNP with the lowest P and 1 or 2 proxy SNPs to accommodate differing genotyping platforms) for attempted replication. SNPs were genotyped in 2 additional cohorts and analyzed within cohort using a similar analysis plan except that observed rather than imputed genotypes were used in the analyses. Results from the 2 replication cohorts were then combined by meta-analysis. We considered a PϽ0.025 (0.05/2) and same direction of effect for the replication meta-analysis as indicative of successful replication.
To assess possible effect modification by age, we performed an age-stratified analysis based on the approximate overall median age of 55 years. For cohorts that spanned this age cutoff (FHS, ERF, Sardinia, ACCT), analyses were repeated in subgroups Ͻ55 and Ն55 years of age. Cohorts with predominantly older (AGES, BLSA, HABC, RS-I, RS-II) or younger (HAPI, Asklepios) participants were included in the older or younger group in their entirety to preserve adequate sample size. These groupings resulted in 9 sets of data consisting of predominantly older participants and 6 sets of data consisting of predominantly younger participants. In addition, because of known associations between CFPWV and clinical events, [1] [2] [3] [4] 8 we performed lookups of the top result from our CFPWV GWAS in separate GWAS meta-analyses for clinical end points thought to be related to arterial stiffness, including coronary artery disease, heart failure, stroke, and kidney disease. We also performed a lookup of our top result in an ongoing pulse pressure GWAS meta-analysis in order to determine whether genetic effects on aortic stiffness were detectable as an increase in blood pressure pulsatility in additional cohorts (see the online-only Data Supplement for details of clinical GWAS meta-analyses).
Results
Characteristics of participants at the time of CFPWV measurement in the 11 (9 discovery, 2 replication) AortaGen Consortium cohorts are presented in Table 1 . Cohort mean age varied from 34 to 75 years, whereas cohort mean CFPWV varied from 5.5 to 13.6 m/s, corresponding to inverse CFPWV of 193-77 ms/m, respectively. Sample sizes varied from 618 to 6033 participants, with an aggregate of 20 634 and 5306 participants in the discovery and replication phases, respectively.
GWAS meta-analysis results from 9 cohorts are summarized in Figure 1 . The quantile-quantile plot shows minimal evidence of test statistic inflation ( gc ϭ1.03) and a sharp divergence from a slope near unity at a probability value of approximately 1ϫ10 Ϫ4 . The negative log P (Manhattan) plot reveals a region of genome-wide significant association on the distal long arm of chromosome 14 (14q32.2, rs1381289, ␤ϭϪ0.073Ϯ0.011 SD/allele, Pϭ5.6ϫ10 Ϫ11 ). Imputation quality for the genome-wide significant SNPs in this region was high, with median expected/observed variance ratio of 0.99 -1.00. In addition, there is a suggestive region of association on the short arm of chromosome 10 (10p12.32, rs10764094, ␤ϭϪ0.057Ϯ0.011 SD/allele, Pϭ2.4ϫ10 Ϫ7 ). A listing of top SNPs from the 9-cohort meta-analysis with a PϽ1ϫ10 Ϫ5 is presented in Table 2 . The table provides results for the top SNP from separate loci defined by linkage disequilibrium (LD) structure (r 2 Ͻ0.80). Results of analyses that further adjusted for mean arterial pressure at the time of CFPWV measurement are presented in online-only Data Supplement Table S3. Comparison of  Tables 2 and S3 reveals that several associations were  relatively stronger after adjustment for mean arterial pressure (CFDP1, FGFR2, NMUR2, ADAMTS9, OCA2,  VPS54) , others were unaffected (C10orf112, EFTUD1, CKAP5), and a few were weakened (ELK3, SLCO5A1, MAFB, CADPS2). For the locus on chromosome 14 (C14orf64), associations for some SNPs were weaker (rs1381289), whereas others were stronger (rs9323989) after adjustment for mean arterial pressure. 
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Based on a preliminary meta-analysis of early GWAS results from 6 cohorts ( Table 1; AGES, FHS, ERF, RS-I,  RS-II, and Sardinia; 17 854 participants) , we selected rs7152623 on chromosome 14 (results from 6 cohorts: ␤ϭϪ0.075Ϯ0.012 SD/allele, Pϭ2.8ϫ10 Ϫ 10 ) and rs17729837 on chromosome 10 (results from 6 cohorts: ␤ϭ0.062Ϯ0.012 SD/allele, Pϭ3.6ϫ10 Ϫ7 ) for attempted replication. Note that rs7152623, the SNP on chromosome 14 selected for replication, falls within the LD block that includes rs1381289 as the SNP with the lowest probability value in the block ( Table 2 ). The 2 SNPs are closely linked (R 2 ϭ0.93 for rs1381289 and rs7152623). We successfully replicated the association with rs7152623 on chromosome 14 (replication ␤ϭϪ0.086Ϯ0.020 SD/allele, Pϭ1.4ϫ 10 Ϫ6 ). Results for rs7152623 from the full set of 11 cohorts gave a combined ␤ϭϪ0.076Ϯ0.010 SD/allele, Pϭ3.1ϫ10 Ϫ15 (Figure 2 ). The effect was attenuated modestly and remained significant when we further adjusted for mean arterial pressure at the time of measurement of CFPWV (␤ϭϪ0.060Ϯ0.009 SD/allele, Pϭ1.0ϫ10 Ϫ11 ). In addition, results were consistent when evaluated separately in subgroups defined by median age, remaining associated in both younger (Ͻ55 years of age, 6 cohorts, nϭ13 914, ␤ϭϪ0.081Ϯ0.014 SD/allele, Pϭ2.3ϫ10 Ϫ9 ) and older (Ն55 years of age, 9 cohorts, nϭ12 026, ␤ϭϪ0.061Ϯ0.014 SD/ allele, Pϭ9.4ϫ10 Ϫ6 ) participants. The association with rs17729837 on chromosome 10 did not replicate (Pϭ0.97).
Details of the region of significant association on chromosome 14 are presented in Figure 3 . The closest known gene (3Ј BCL11B) is nearly 1 MB telomeric to this locus. The associated SNPs are located in a block of LD spanning from approximately 97.60 -97.74 MB, which corresponds closely with the location of a cluster of previously documented, overlapping, spliced expressed sequence tags (ESTs), including DB129663 and BP432414, which are on the minus and plus strand, respectively. One of our highly associated SNPs (rs710285, Pϭ5.1ϫ10 Ϫ11 ) is located in exon 3 of DB129663. In addition, there is a conserved sequence near the center of the chromosome 14 locus (97.67 MB, Figure  3 ), in overlapping intronic regions of DB129663 and BP432414.
To assess potential functional implications of our findings, we used reverse transcriptase polymerase chain reaction (RT-PCR) to evaluate expression of DB129663 and BP432414 in human aortic samples and various cell lines. In light of the putative role of this region as a remote enhancer of BCL11B 9 and relative proximity to VRK1, we also probed for expression of these genes (online-only Data Supplement Table S4 ). DB129663, BP432414, BCL11B, and VRK1 were detected in whole aortic rings (online-only Data Supplement Table S4 ). VRK1 and DB129663 were expressed in cultured aortic smooth muscle cells, human umbilical vein endothelial cells (HUVECs), and adult cardiac fibroblasts. BCL11B was expressed in the same samples except cardiac fibroblasts. All transcripts were expressed in CD3ϩ cells.
To assess the potential clinical relevance of our finding of a locus on Chr14 strongly associated with CFPWV, we performed a lookup of our top SNP for association with CFPWV in the meta-analysis of 9 cohorts (rs1381289, To aid interpretation of these CVD end point associations, we used data from FHS to estimate the expected HR for a first major CVD event associated with presence of each allele of rs1381289, assuming that excess CVD risk was mediated by effects of the allele on CFPWV. 4 In FHS, after adjusting for age and sex, CFPWV was associated with an excess CVD risk corresponding to an HRϭ1.65 per SD. Based on this estimate, and given that each minor allele of rs1381289 was associated with a 0.073 SD increase in CFPWV, the expected HRϭ1.047 per allele, which is comparable to the GWAS lookup results. In a separate meta-analysis that included 74 011 participants, rs1381289 was associated with higher pulse pressure (␤ϭ0.18Ϯ0.06 mm Hg/allele, Pϭ0.002), indicating that the increase in aortic stiffness associated with this SNP is detectable as a modest but significant increase in pressure pulsatility. The SNP was not associated with stroke (PϾ0.7), glomerular filtration rate estimated by using serum creatinine (PϾ0.6) or cystatin (PϾ0.5), or prevalent chronic kidney disease (PϾ0.6).
We also sought to replicate a previously reported association between CFPWV and a SNP (rs3742207) in COL4A1. 10 After excluding 2 cohorts involved in the original report (Sardinia, HAPI), we found modest evidence of association for this SNP (rs3742207, ␤ϭϪ0.025Ϯ0.011 SD/allele, Pϭ0.017) (online-only Data Supplement Figure S1 ).
Discussion
We performed a meta-analysis of GWAS results for CFPWV from 9 community-based cohorts involving 20 634 participants spanning a broad age range and identified a locus of genome-wide significant association in an apparent gene desert on 14q32.2. This finding was replicated in 2 additional cohorts involving 5306 participants. We identified a conserved sequence within the region of significant association surrounded by a cluster of primatespecific, noncoding RNAs (ncRNAs). We evaluated 2 of these ncRNAs, which have at least 1 associated SNP within an exon and demonstrated that they are expressed in relevant human cardiac and vascular tissues and cell lines, including full thickness aortic rings, aortic smooth muscle cells, cardiac fibroblasts, and HUVECs. In light of the putative role of the region of significant association as a gene enhancer, 9, 11, 12 we also assayed for and demonstrated expression of flanking known genes, BCL11B and VRK1, in the same tissues and cell lines. Our findings indicate that the VRK1-BCL11B gene desert harbors a regulatory locus that modulates aortic stiffness. The association was consistent in younger and older participants, suggesting that the effects on CFPWV of genetic variation at this locus manifest early in life, before the marked increase in CFPWV that occurs from midlife onward. In addition, we demonstrated that the locus is associated with increased risk for cardiovascular disease, consistent with the hypothesis that increased aortic stiffness, as assessed by CFPWV, plays a causal role in the pathogenesis of cardiovascular disease. Further elucidation of potential mechanisms of aortic stiffening mediated through this locus may provide novel insights into the pathogenesis of aortic stiffening and could potentially offer insights into currently unavailable targeted interventions that prevent or attenuate aortic stiffening with advancing age and reduce the associated excess risk for major CVD events.
CFPWV has emerged recently as an important risk factor for various afflictions of aging, including CVD, cognitive dysfunction and chronic kidney disease. CFPWV is easily and reproducibly measured in a few minutes using relatively inexpensive technology and is widely considered the present gold standard noninvasive measure of aortic stiffness. Aside from age, with which it is strongly related, CFPWV has consistent but relatively modest relations with standard CVD risk factors and is moderately heritable, rendering the phenotype optimal for genetic studies.
A number of prior studies have evaluated potential genetic correlates of various measures of arterial stiffness including CFPWV. Family-based studies have identified several regions of potential linkage for stiffness measures using a microsatellite-based whole genome approach. 6 Genetic association studies have found relations between measures of arterial stiffness and polymorphisms in various candidate genes, including genes for the angiotensin II type 1 receptor, 13 fibrillin-1, 14 angiotensin-converting enzyme, 15, 16 ␣-adducin, 15 aldosterone synthase, 15,17 ␤-adrenergic receptors, 18 endothelin A and B receptors, 19 matrix metalloproteinases 3 and 9, 20,21 endothelial nitric oxide synthase, 22 the large conductance calcium-activated potassium channel, 23 estrogen genes 24 and various inflammatory genes. 25, 26 However, small sample sizes, ascertainment bias (hypertensive, known coronary artery disease, etc) and relatively weak associations may have limited the generalizability and consistency of findings. Notably, none of the aforementioned candidate genes are in the top hits of the present analysis (Tables 2 and S3 ). Two prior CFPWV GWAS publications 10, 27 were similarly based on relatively small sample sizes and employed less dense genotyping, which limited power to detect associations. A relative paucity of genome-wide significant findings remains a concern with our present publication involving 9 discovery and 2 replication cohorts and an aggregate sample size of nearly 26 000 individuals. Additional work and larger samples will be required to determine whether any additional loci in the group of excess low probability values below Ϸ1ϫ10 Ϫ4 are true positive associations.
Prior studies provide evidence that the region of association with CFPWV that we have identified on 14q32.2 lies in the vicinity of 1 or more gene enhancers. The region encompasses various regulatory features, including several DNAse-I hypersensitive sites and transcription factor binding sites and high levels of nuclear matrix attachment. 9, 11, 12 Chromatin modifications in the region, including high levels of acetylation of histone 3 at lysine 27 (H3K27) and monomethylation at lysine 4 (H3K4) assessed in a lymphoblastoid cell line, are consistent with enhancer function (http://genome.ucsc. edu). 28 Despite considerable genomic separation from the enhancer cluster (Ϸ1 MB telomeric), BCL11B is thought to be a target of one or more of the enhancers in this locus. 9, 11, 12 BCL11B is located on the minus strand, positioning the enhancer cluster in the remote 3Ј region of the gene. The closest known gene in the opposite direction, VRK1, isϷ1.1 MB centromeric to the enhancer cluster and is on the plus strand, again positioning the enhancer in the remote 3Ј region of VRK1, suggesting that one or both genes could potentially be targets of a remote 3Ј enhancer in this region.
In support of BCL11B as a target, numerous translocations have been described that insert fragments of 5q35 at various positions in a breakpoint cluster region that falls between the enhancer region and 3Ј BCL11B. These translocations interpose the homeobox genes TLX3 or NKX2-5 between the enhancer region and 3Ј BCL11B and result in ectopic activation of the inserted homeobox gene, dysregulated T-cell proliferation, and acute T-cell lymphoblastic leukemia. 9, 11, 12 T-cell regulatory signals directed at BCL11B may interact with the enhancer to drive ectopic activation of the interposed homeobox gene, leading to cell-specific malignant transformation. Su et al used translocation data to map enhancer function to a 58-kB segment of the genome that corresponds to the telomeric shoulder of our locus of significant association with CFPWV. 12 Relative proximity of the enhancer to BCL11B, the important role that BCL11B plays in T-cell development and the T-cell specificity of malignant transformations involving translocations into the region support the hypothesis that BCL11B is a target of this enhancer.
BCL11B codes for chicken ovalbumin upstream promoter transcription factor (COUP-TF) interacting protein 2 (CTIP2), which is a cofactor in the COUP-TF family of transcription factors 29 and a direct transcriptional repressor. 30 There are several potential mechanisms for an effect of BCL11B on aortic stiffness. COUP-TFII (NR2F2) modulates the angiopoietin-1 and vascular endothelial growth factor pathways and plays a critical role in the development of the heart and great vessels. 31 In addition, BCL11B is a C 2 H 2 zinc finger protein that can directly bind DNA in a sequence specific manner. Acting in part through an interaction with SIRT1, BCL11B can effect transcriptional repression of various genes that may be relevant to aortic stiffness. [32] [33] [34] [35] In addition to direct effects of BCL11B on aortic function, there are potential indirect effects mediated through the known role that BCL11B plays in T-cell function. T-cell-specific deletion of BCL11B at the CD4ϩ single positive stage is associated with increased numbers of proinflammatory T-cells that could potentially infiltrate the aorta and promote inflammation, fibrosis, and stiffening. 36, 37 Additional work will be required to establish the potential role that genetic variation in the chromosome 14 locus may play in BCL11B expression and aortic function.
We demonstrated that 2 overlapping ESTs that fall completely within the region of highly significant association with CFPWV are expressed in aortic tissue and cell lines. These primate-specific, potentially regulatory ncRNAs are expressed in cDNA extracts from full-thickness human aortic rings and various human cell lines, including aortic smooth muscle cells, HUVECs, and cardiac fibroblasts. One of the highly associated SNPs in the region (rs710285) is located in an exon of DB129663, suggesting a possible functional effect. The enhancer core region mapped by Su et al corresponds to the putative promoter region of DB129663. Thus, enhancer function at our chromosome 14 locus may target DB129663, which appears to be an ncRNA of unknown function. Additional work will be required to test this hypothesis and further define the function of DB129663 and other ncRNAs in the region.
Several additional SNPs with suggestive associations to CFPWV (10 Ϫ8 ϽPϽ10 Ϫ5 ) may merit further consideration and additional replication genotyping. The locus on chromosome 10 with the second lowest probability value in our GWAS meta-analysis lies in the vicinity of a putative protein coding gene that may represent a novel member of the low density lipoprotein receptor-related protein (LRP) family. 38 We found moderate evidence for association at the LRP4 locus, which is also associated with stroke 39 and bone mineral density. 40, 41 The LRP4 locus includes a nonsynonymous SNP (rs6485702) that has been related to bone mineral density, 40 although a separate report involving several of our cohorts positioned the region of highest association with bone mineral density in the promoter region of ARHGAP1. 41 Bone density and arterial stiffness are related phenotypes 42 that may share many common pathways. The recently observed inhibitory role that LRP4 plays in Wnt signaling in bone 43 coupled with the adverse effects of Wnt signaling in the aorta 44 suggests that a mutation that impairs the ability of LRP4 to modulate the Wnt signaling cascade could simultaneously contribute to osteopenia and aortic stiffening. The chromosome 11 locus that encompasses LRP4 and additional potential candidates, including ARHGAP1 and F2, represents a long LD block that was also associated with stroke in a prior meta-analysis that included several of the cohorts in our study. 39 The direction of effect in the prior study (higher risk for the minor allele) and ours (stiffer aorta with the minor allele) was consistent with the known association between increased CFPWV and increased risk for stroke. In addition, a prior family-based linkage analysis for myocardial infarction found a single significant linkage peak in the vicinity of our chromosome 14 locus. 45 These regions of overlap with prior results involving separate but related phenotypes support the clinical relevance of our associations and suggest that several genetic variants that impact CFPWV may eventually manifest as age-related morbidity and major cardiovascular events.
We also attempted to replicate a previously reported association of CFPWV with a SNP in the COL4A1 locus in the only published GWAS that has evaluated CFPWV. 10 The present results found modest evidence of association with some heterogeneity of effect, suggesting that additional work will be required to determine whether variation in LD patterns or other factors could potentially account for heterogeneous effects at this locus.
There are limitations of our study that should be considered. The cohorts comprised exclusively white participants of European descent. Thus, our findings may not generalize to other populations. Slightly different methods were used to assess CFPWV in the various cohorts. However, our use of standardized residuals generated within each cohort should have minimized the effects of these technical differences between studies. A major strength of our study is the use of data from 11 large community-based cohorts that routinely ascertained CF-PWV, which should enhance generalizability of our findings.
In conclusion, we performed the first large-scale GWAS of CFPWV, which is a moderately heritable measure of aortic stiffness and important risk factor for cardiovascular events. We identified a highly significant locus of association at 14q32.2 in the VRK1-BCL11B gene desert in an LD block that harbors 1 or more gene enhancers. We have also shown that genetic variation at this locus is associated with increased risk for major CVD events, providing strong support for the hypothesis that increased CFPWV contributes to the pathogenesis of CVD. We have shown that 2 potentially regulatory ncRNAs as well as flanking genes, BCL11B and VRK1, are expressed in human aorta. Further work will be required to define precise mechanisms mediating the association between CFPWV and genetic variation in the VRK1-BCL11B gene desert. Elucidation of pathways affected by this locus will provide new insights into the process of aortic stiffening in humans and could yield potential targets for specific interventions that reverse or attenuate aortic stiffening and prevent the associated morbidity and mortality.
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CLINICAL PERSPECTIVE
Carotid-femoral pulse wave velocity (CFPWV) is a heritable measure of aortic stiffness that is strongly associated with increased risk for major cardiovascular disease events. However, the molecular mechanisms contributing to aortic stiffness remain largely undefined. To evaluate associations of common genetic variants with CFPWV, we conducted a meta-analysis of genome-wide association data in 9 community-based European ancestry cohorts consisting of 20 634 participants. Results were replicated in 2 additional European ancestry cohorts involving 5306 participants. We identified a highly significant locus of association at 14q32.2 in the VRK1-BCL11B gene desert in a linkage disequilibrium block that harbors 1 or more gene enhancers. We also showed that variation at this locus is associated with increased risk for major cardiovascular disease events, providing strong support for the hypothesis that increased CFPWV contributes to the pathogenesis of cardiovascular disease. We demonstrated that 2 ncRNAs as well as flanking genes, BCL11B and VRK1, are expressed in human aorta. Further work will be required to define precise mechanisms mediating the association between CFPWV and genetic variation in the VRK1-BCL11B gene desert. Elucidation of pathways affected by this locus will provide new insights into the process of aortic stiffening in humans and could yield potential targets for specific interventions that reverse or attenuate aortic stiffening and prevent the associated morbidity and mortality.
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A reexamination of survivors from AGES-RS is presently being conducted (AGES-II).
Arterial tonometry was added to the original AGES-RS study protocol for all participants beginning January 12, 2005 and continuing through to the end of the examination cycle.
Arterial tonometry is being assessed in all participants in AGES-II. Carotid-femoral pulse wave velocity (CFPWV) was evaluated by tonometry and calculated from the foot-tofoot delay between carotid and femoral waveforms and body surface measurements that adjusted for parallel transmission in the carotid and aorta by using the suprasternal notch as a fiducial point. Successful genotyping was available for 3,219 AGES-RS participants, of whom 967 had successful measurement of CFPWV. The AGES-RS GWAS was approved by the National Bioethics Committee and the Data Protection Authority.
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The Baltimore Longitudinal Study of Aging (BLSA) is an observational study that began in 1958 to investigate normative aging in community dwelling adults who were healthy at study entry. 2 Participants are examined every one to four years depending on their age. Currently there are approximately 1,100 active participants enrolled in the study. Blood samples were collected for DNA extraction, and genome-wide genotyping was completed for 1,231 subjects using Illumina 550K. This analysis focused on a subset of the participants (N=610) of European ancestry for whom CFPW was available. The Rotterdam Study (RS) is a prospective population-based cohort study comprising 7,983 subjects (78% response rate) aged 55 years or older. 9 Baseline data (RS-I) were collected between 1990 and 1993. In 1999, inhabitants who turned 55 years of age or moved into the study district since the start of the study were invited to participate in an extension of the RS (RS-II) of whom 3,011 participated (67% response rate). The rationale and design of the RS have been described in detail elsewhere.
France) and calculated from the simultaneously measured foot-to-foot time delay between carotid and femoral pressure waves and body surface measurement of the distance between carotid and femoral pulse recording site. All RS participants with available DNA were genotyped using Illumina Infinium II HumanHap BeadChips at the Department of Internal Medicine, Erasmus Medical Center following manufacturer's protocols. Participants with call rate < 97.5%, excess autosomal heterozygosity, sex mismatch, or outlying identity-by-state clustering estimates were excluded. After quality control 5,974 RS-I participants and 2,157 RS-II participants were included. Of these, 3,011 RS-I participants and 1,657 RS-II participants had successful measurement of CFPWV.
The SardiNIA Study is a longitudinal study of aging-related quantitative traits comprising individuals from a circumscribed region on the island of Sardinia, Italy. The sample constitutes a genetically isolated founder population by virtue of their geographic isolation and ethnic homogeneity. In the SardiNIA study, 6,148 men and women over the age of 14 were recruited from a cluster of four towns in the Lanusuei Valley in the Ogliastra province of the island, which has a total population of 11,000. delay between carotid and femoral waveforms and body surface measurements that adjusted for parallel transmission in the carotid and aorta by using the manubrium as a fiducial point. CFPWV and genotype data was available in 4,216 subjects.
Replication Sites
The Anglo Cardiff Collaborative Trial (ACCT) consists of ~12,000 community-derived individuals selected at random from the local general practice lists and open-access cardiovascular risk assessment clinics across East Anglia and Wales in the United Kingdom.
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Approval for studies was obtained from the local research ethics committees, and written informed consent obtained from each participant. The overall response rate was 85%. All participants completed a detailed questionnaire and measurements were conducted in a quiet temperature controlled room. Height and weight were assessed with standard methods. After 20 minutes of supine rest, peripheral blood pressure was recorded in the brachial artery of the non-dominant arm using a validated oscillometric technique (HEM-705 CP, Omron Corporation). CFPWV was measured using tonometry and calculated from the foot-to-foot delay between carotid and femoral waveforms and body surface measurements that adjusted for parallel transmission in the carotid and aorta by using the suprasternal notch as a fiducial point as described previously. 
Clinical Endpoint Consortia
The Coronary ARtery DIsease Genome-wide Replication And Meta-analysis For all participating studies, genome-wide scans were performed using either Affymetrix or Illumina platforms followed by imputation of genotypes. Statistical methods have been standardized across studies. Pulse pressure was defined as systolic blood pressure minus diastolic blood pressure. The combined analyses included 74,011 subjects.
The neuroCHARGE consortium combined data from white participants in four large, prospective population based cohort studies: ARIC, CHS, FHS, and RS to study the genetics of stroke. 18 All participating studies approved guidelines for collaboration, and a neurology working-group arrived at a consensus on phenotype harmonization, covariate selection and analytic plans for within-study analyses and meta-analysis of results. Each study has an Institutional Review Board that approved the consent procedures, examination and surveillance components, data security processes, genotyping protocols and current study design. Stroke was defined as a focal neurologic deficit of presumed vascular cause with a sudden onset and lasting for at least 24 hours or until death if the participant died less than 24 hours after the onset of 14 symptoms. The combined analysis included 1544 incident strokes (1164 ischemic strokes) among 19,602 persons followed for an average of 11 years.
The CKDGen consortium performed a genome-wide association meta-analysis in 67,093 study participants of European ancestry from 20 predominantly populationbased cohorts. Table S2 ). Amplification products of appropriate size were excised from agarose gel and purified with QIAquick Gel Extraction Kit (Qiagen Inc); recovered DNA fragments were cloned with TOPO TA Cloning® Kit (Invitrogen Inc). Three independent clones for each sample were selected for follow-up sequencing to avoid possible reading errors. We used BigDye® Terminator v1.1 kit (Applied Biosystems Inc) for sequencing reaction and samples were analyzed on a 3130xl Genetic Analyzer (Applied Biosystems Inc).
Total RNA was extracted from human aortic tissue using the TRIzol® Plus RNA Purification System (Invitrogen). Extraction of RNA was conducted according to the manufacturer's protocol and was further purified using PureLink™ silica-gel spin columns followed by DNase I digestion to minimize genomic DNA contamination (Invitrogen, PureLink™ RNA Mini Kit). First strand cDNA synthesis was performed on 1 g total RNA using AMV reverse transcriptase according to manufacturer instructions (Reverse Transcription System, Promega). Reverse transcription was initiated using random hexamer primers and the reaction carried out at 42°C for 60 min, followed by heat inactivation at 95°C for 5 min. PCR primers were designed to target BP432414, DB129663, BCL11B and VRK1 (Supplementary Table S2 for 15 s, and 72°C for 15 s, with a final extension of 72°C for 10 min. To verify that the amplified product was the targeted gene, the product from one sample was sequenced at Geneservice (www.geneservice.co.uk) using Sanger sequencing followed by analysis on Applied Biosystems 3730 DNA Analyzer. 
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